Clinical trials

Filter By

HM-EZHI-101

Phase 1

Open and recruiting

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Read more: A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
CODEBREAK 202

Phase 3

Open and recruiting

Lung Cancer KRAS G12C

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Read more: Lung Cancer KRAS G12C
BIOATLA BA3701

Phase 1, Phase 2

Open and recruiting

Advanced or metastatic solid tumours – Bioatla

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Read more: Advanced or metastatic solid tumours – Bioatla
ASCENDIS 1L

Phase 1, Phase 2

Open and recruiting

Advanced or metastatic solid tumours – TransCon IL-2 β/γ

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile…
Read more: Advanced or metastatic solid tumours – TransCon IL-2 β/γ
ARTISTRY 7

Phase 3

Open and recruiting

Ovarian – Platinum Resistant

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read more: Ovarian – Platinum Resistant

Filter By

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Lung Cancer KRAS G12C

Advanced or metastatic solid tumours – Bioatla

Advanced or metastatic solid tumours – TransCon IL-2 β/γ

Ovarian – Platinum Resistant